Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... acute myeloid leukaemia (<30% bone marrow blasts , n = 102), there was a statistically significant reduction in ...

    Research Article last updated 08/04/2014 - 8:37am.

  2. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

    ... such as additional chromosomal abnormalities, >5 % blasts in the bone marrow (BM), or transfusion dependence. Over ...

    Research Article last updated 09/17/2013 - 2:05pm.

  3. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... included Intermediate-1 (n=5 patients with excess blasts ), Intermediate-2 (20), and High (11). Common grade 3/4 ...

    Research Article last updated 10/01/2012 - 9:58am.

  4. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

    ... (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and ...

    Research Article last updated 06/20/2013 - 11:02am.

  5. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... patients with refractory anemia with excess of blasts (RAEB) type 1, 18 patients with RAEB type 2 and four patients with ...

    Research Article last updated 06/15/2012 - 2:13pm.

  6. Paroxysmal nocturnal hemoglobinuria in pediatric patients.

    ... myelodysplastic features without developing excessive blasts or leukemic transformation. Thrombosis occurred in 6 patients. Five ...

    Research Article last updated 12/12/2011 - 10:07am.

  7. Prognosis of myelodysplastic syndromes.

    ... that include morphological features, percentage of blasts , and clinical and molecular characteristics such as peripheral ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... myeloid leukemia with 20% to 30% bone marrow blasts . METHODS: This secondary analysis of the AZA-001 phase 3 study ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. The search for better prognostic models in myelodysplastic syndromes.

    ... to acute myeloid leukemia based on the percentage of blasts , karyotype, and number of cytopenias, but the IPSS has several ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... three patients who relapsed on monotherapy with excess blasts at 12, 19, and 24 months, in whom lenalidomide was then resumed in ...

    Research Article last updated 10/11/2011 - 5:58pm.